Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 1.00 |
| ▸ | NPC1 | O15118 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 4/20 | 1.00 |
| ▸ | RELA | Q04206 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7015854 | 0.84 | NPC1 (0.72) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL3859410 | 0.82 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL9384187 | 0.80 | NPC1 (0.72) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL3870512 | 0.79 | GRM5 (0.74) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL1131467 | 0.78 | SMN1; SMN2 (1.00) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL31565184 | 0.77 | KDR (0.64) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL27882364 | 0.77 | NPC1 (0.62) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL16996703 | 0.77 | NPC1 (0.62) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL28310352 | 0.77 | RAB9A (0.79) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL13381527 | 0.77 | HDAC8 (0.76) | RAB9ANPC1SMN1; SMN2TP53NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0642343-A1 | TREATMENT OF CANCERS | XENOVA LIMITED (GB) | 1995-03-15 | — | — | EP | claimed |
| WO-1993024096-A2 | USE OF N-(2-(DIMETHYLAMINO)ETHYL)ACRIDINE-4-CARBOXAMIDE AND ITS ANALOGUES FOR CANCER TREATMENT | XENOVA LIMITED (GB) | 1993-12-09 | — | — | WO | claimed |
| EP-1715867-A4 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-06-28 | — | — | US | disclosed |
| EP-1715867-A1 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005079802-A1 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005079802-A1 | BIPYRIDYL AMIDES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149547-A1 | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GABRA5 | RAB9A 1748/4885NPC1 3248/4885SMN1; SMN2 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.